"Johnson & Johnson" vaccine for "Corona" stimulates a strong immune response in early trials

Interim results published, Friday, showed that a single dose of Johnson & Johnson's experimental Covid-19 vaccine stimulated a strong immune response to prevent the emerging corona virus in an early to medium-stage clinical trial. 

The results showed that the vaccine, called AD26 Coff2S, was equally well tolerated in two different doses.

But it is not clear if the elderly, who are one of the population groups most at risk of contracting the virus, will enjoy the same protection as younger people from the J&J vaccine.

The trial on nearly a thousand healthy adults, which is supported by the US government, began after it was discovered in July that a single dose of the vaccine provides strong protection for monkeys.

Based on current results, the company on Wednesday began a final trial with 60,000 people that could pave the way to apply for regulatory approval.

The company said it expects the results of the so-called Phase III trial by the end of the year or early next year. 

Follow our latest local and sports news, and the latest political and economic developments via Google news